Ranjini Roy1, Chandrima Pattadar1, Rishav Raj1, Neeraj Agarwal2, Bijit Biswas3, Pramod Kumar Manjhi4, Deependra Kumar Rai5, Anjani Kumar6, Asim Sarfaraz7. 1. Postgraduate Trainee, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India. 2. Professor and Head, Department of Community and Family Medicine, All India Institute of Medical Sciences, Bibinagar, Telangana, India. 3. Senior Resident, Department of Community and Family Medicine, All India Institute of Medical Sciences, Patna, Bihar, India. 4. Assistant Professor and Head, Department of Pharmacology, All India Institute of Medical Sciences, Patna, Bihar, India. 5. Additional Professor and Head, Department of Pulmonary Medicine, All India Institute of Medical Sciences, Patna, Bihar, India. 6. Assistant Professor, Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India. 7. Assistant Professor, Department of Microbiology, All India Institute of Medical Sciences, Patna, Bihar, India.
Abstract
BACKGROUND: There has been a growing interest in ivermectin ever since it was reported to have an in-vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This trial was conducted to test the efficacy of ivermectin in mild and moderate coronavirus disease 19 (COVID-19). METHODS: A double blind, parallel, randomised, placebo-controlled trial conducted among adult COVID-19 patients with mild to moderate disease severity on admission in a COVID dedicated tertiary healthcare of eastern India. Enrolment was done between 1st August and 31st October 2020. On day 1 and 2 post enrolment, patients in the intervention arm received ivermectin 12 mg while the patients in the non-interventional arm received placebo tablets. RESULTS: About one-fourth (23.6%) of the patients in the intervention arm and one-third (31.6%) in the placebo arm were tested reverse transcriptase polymerase chain reaction (RTPCR) negative for SARS-CoV-2 on 6th day. Although this difference was found to be statistically insignificant [rate ratio (RR): 0.8; 95% confidence interval (CI): 0.4-1.4; p=0.348]. All patients in the ivermectin group were successfully discharged. In comparison the same for the placebo group was observed to be 93%. This difference was found to be statistically significant (RR: 1.1; 95% CI; 1.0-1.2; p=0.045). CONCLUSIONS: Inclusion of ivermectin in treatment regimen of mild to moderate COVID-19 patients could not be said with certainty based on our study results as it had shown only marginal benefit in successful discharge from the hospital with no other observed benefits.
RCT Entities:
BACKGROUND: There has been a growing interest in ivermectin ever since it was reported to have an in-vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This trial was conducted to test the efficacy of ivermectin in mild and moderate coronavirus disease 19 (COVID-19). METHODS: A double blind, parallel, randomised, placebo-controlled trial conducted among adult COVID-19patients with mild to moderate disease severity on admission in a COVID dedicated tertiary healthcare of eastern India. Enrolment was done between 1st August and 31st October 2020. On day 1 and 2 post enrolment, patients in the intervention arm received ivermectin 12 mg while the patients in the non-interventional arm received placebo tablets. RESULTS: About one-fourth (23.6%) of the patients in the intervention arm and one-third (31.6%) in the placebo arm were tested reverse transcriptase polymerase chain reaction (RTPCR) negative for SARS-CoV-2 on 6th day. Although this difference was found to be statistically insignificant [rate ratio (RR): 0.8; 95% confidence interval (CI): 0.4-1.4; p=0.348]. All patients in the ivermectin group were successfully discharged. In comparison the same for the placebo group was observed to be 93%. This difference was found to be statistically significant (RR: 1.1; 95% CI; 1.0-1.2; p=0.045). CONCLUSIONS: Inclusion of ivermectin in treatment regimen of mild to moderate COVID-19patients could not be said with certainty based on our study results as it had shown only marginal benefit in successful discharge from the hospital with no other observed benefits.
Authors: Halie M Rando; Nils Wellhausen; Soumita Ghosh; Alexandra J Lee; Anna Ada Dattoli; Fengling Hu; James Brian Byrd; Diane N Rafizadeh; Ronan Lordan; Yanjun Qi; Yuchen Sun; Christian Brueffer; Jeffrey M Field; Marouen Ben Guebila; Nafisa M Jadavji; Ashwin N Skelly; Bharath Ramsundar; Jinhui Wang; Rishi Raj Goel; YoSon Park; Simina M Boca; Anthony Gitter; Casey S Greene Journal: mSystems Date: 2021-11-02 Impact factor: 6.496
Authors: Nilima Dinesh Kumar; Bram M Ter Ellen; Ellen M Bouma; Berit Troost; Denise P I van de Pol; Heidi H van der Ende-Metselaar; Djoke van Gosliga; Leonie Apperloo; Orestes A Carpaij; Maarten van den Berge; Martijn C Nawijn; Ymkje Stienstra; Izabela A Rodenhuis-Zybert; Jolanda M Smit Journal: Antimicrob Agents Chemother Date: 2021-10-11 Impact factor: 5.191